Dear Reader, Well... well, would you look at that. The government “shut down.” Politicians screamed disaster. Cable news ran their doomsday graphics. And the market? The S&P 500 and Nasdaq just hit new all-time highs. Exactly like I told you yesterday. Stock futures dipped overnight. Just enough to shake out the nervous money. Then reality kicked in. TINA took over. Just like Frank Sinatra sang it: “Tina, Tina, nobody else but Tina.” And stocks did what they always do when there’s nowhere else for money to go. They went up. The Numbers Tell the Real StoryToday’s option volume: 66.1 million contracts. Standard day. Nothing special. Except calls crushed puts 5 to 3. That’s conviction, not caution. While Washington performed its shutdown theater, real money was buying. Just like that $4 million TQQQ bet I showed you yesterday. The pattern never changes. The 410% Trade Nobody’s WatchingBut forget the indexes for a second. The most interesting action today wasn’t in tech or AI. It was in biotech—specifically XBI, the biotech ETF everyone forgot about.
While the world obsessed over semiconductors, someone quietly turned $1.75 into $8.93 per contract. That’s a 410% gain in two months. And today? They doubled down with another $2.6 million. How This Money Train Started RollingAugust: This firm bought 10,000 November $95 calls at $1.75 each. Biotech was dead. All eyes on AI. Perfect entry. Last week: They started “rolling” the position. Let me demystify that—they sold their winning $95 calls for $5.60 each, banking profits. Then immediately bought higher strike calls with the proceeds. It’s like trading in your Honda for a Mercedes, except the dealer pays you to upgrade. Today: They closed the remaining position at $8.93. From $1.75 to $8.93. While everyone else watched shutdown countdown clocks. Why They’re Betting Even Bigger NowAfter banking 410%, most traders disappear to the Bahamas. Not these guys. They took those profits—plus fresh capital—and bought 10,000 November $106 calls at $2.64 each.
That’s $2.64 million in new premium. XBI closed today at $101.39. They need it above $106 by November 21st. Just 5% upside from here, and they win again. You don’t risk $2.6 million on 5% unless you’re seeing something others aren’t. The Biotech Perfect Storm BrewingHere’s what’s actually driving this trade: The Fed cut rates in September. October’s cut is 96% certain. For biotech companies that burn cash developing drugs, cheaper money is oxygen. They can survive longer, develop more, and attract more investment. Meanwhile, the FDA turned into Santa Claus. Nearly 70 drug approvals and label expansions are expected in 2025. Each approval is a potential catalyst. Seventy catalysts in one year. When was the last time you saw that? Plus Big Pharma has a growth problem. Their solution? Buy innovation. Biotech M&A is surging in 2025. Small biotechs with promising drugs become acquisition targets overnight. Rate cuts fuel survival. FDA approvals create value. Big Pharma brings buyouts. That’s not one catalyst—it’s three, all hitting simultaneously. Following Smart Money’s FootprintsThis trader nailed the August bottom. Rode it up 410%. And instead of celebrating, they’re repositioning for the next leg. Institutional money doesn’t pyramid positions out of greed. They do it when probability shifts in their favor. When risk/reward tilts so far that NOT betting would be the mistake. In a sector getting three separate catalysts. While everyone else watches Washington. Your Move While Others Watch PoliticsThe shutdown ends when it ends. History says within two weeks, probably before someone’s vacation. But this biotech rotation is happening now. XBI broke $100. Smart Money says it’s heading to $106. The FDA’s approving drugs. Pharma’s buying companies. The Fed’s cutting rates. Someone who turned $1.75 into $8.93 just placed their next bet. Political theater gets headlines. Smart Money gets profits. Which one are you watching? Trade smart. Until tomorrow, Josh Belanger Disclaimer: Some of the links above are part of paid promotions. If you take action, we may earn a small commission. I only share stuff I believe is worth your attention. Josh Belanger's results are not typical and are not a guarantee of your success. Josh is an experienced investor and your results will vary depending on education, work experience, and background. Josh does not personally participate in every investment alert he provides. Due to sensitivity of financial information, we do not know or track the typical results of our students. Josh’ strategies may not always be accurate, and his investments may not always be profitable. They could result in a loss of an entire investment. We cannot guarantee that you will make money or that you will be successful if you employ his trading strategies specifically or generally. Consequently, your results may significantly vary from his. We do not give investment, tax, or other professional advice. Reference to specific securities should not be construed as a recommendation to buy, sell or hold that security. Specific securities are mentioned for informational purposes only. All investments involve risk, and the past performance of a security, industry, sector, market, financial product, investment strategy, or individual’s investment does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. Such decisions should be based solely on an evaluation of their financial circumstances, investment objectives, risk tolerance, and liquidity needs.
|
Rabu, 01 Oktober 2025
The $2.6 Million Shutdown-Proof Trade
Langganan:
Posting Komentar (Atom)
Tidak ada komentar:
Posting Komentar